Literature DB >> 16088808

Hospital-based study of the economic burden associated with rotavirus diarrhea in Hong Kong.

E Anthony S Nelson1, John S Tam, Ly-Mee Yu, Ying-Chu Ng, Joseph S Bresee, Kin-Hung Poon, Chi-Hang Ng, Kin-Sing Ip, T Christopher Mast, Paul K-S Chan, Umesh D Parashar, Tai-Fai Fok, Roger I Glass.   

Abstract

BACKGROUND: Rotavirus infection is the most common cause of severe diarrhea in both developed and developing countries.
METHODS: To estimate the economic burden associated with rotavirus infection in Hong Kong, we combined data on the disease burden of rotavirus-associated hospital admissions with detailed cost data for a subsample of 471 children with diarrhea admitted to hospitals.
RESULTS: The annual total social cost and total direct medical cost for rotavirus-associated admissions were calculated as 4.3 US dollars and 4 million US dollars, respectively, by use of data collected during March 2001 to March 2003. The estimate of the direct medical costs was approximately 4-fold higher than a previous estimate; this difference largely reflects the greater disease burden identified through active disease surveillance conducted under the auspices of the Asian Rotavirus Surveillance Network. On average, families spent 120 US dollars when their child's admission was associated with rotavirus infection; this cost represents approximately 10% of the monthly salary of an unskilled or service worker.
CONCLUSIONS: These data emphasize the potential for a safe and effective rotavirus vaccine to reduce the economic burden associated with rotavirus disease.

Entities:  

Mesh:

Year:  2005        PMID: 16088808     DOI: 10.1086/431493

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Cost-effectiveness of rotavirus vaccination in Bolivia from the state perspective.

Authors:  Emily R Smith; Emily E Rowlinson; Volga Iniguez; Kizee A Etienne; Rosario Rivera; Nataniel Mamani; Rick Rheingans; Maritza Patzi; Percy Halkyer; Juan S Leon
Journal:  Vaccine       Date:  2011-09-02       Impact factor: 3.641

2.  Prevalence of G2P[4] and G12P[6] rotavirus, Bangladesh.

Authors:  Mustafizur Rahman; Rasheda Sultana; Giasuddin Ahmed; Sharifun Nahar; Zahid M Hassan; Farjana Saiada; Goutam Podder; Abu S G Faruque; A K Siddique; David A Sack; Jelle Matthijnssens; Marc Van Ranst; Tasnim Azim
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

3.  Measuring the Impact of Rotavirus Acute Gastroenteritis Episodes (MIRAGE): A prospective community-based study.

Authors:  Martin Sénécal; Marc Brisson; Marc H Lebel; John Yaremko; Richard Wong; Lee Ann Gallant; Hartley A Garfield; Darryl J Ableman; Richard L Ward; John S Sampalis; James A Mansi
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

4.  Estimates of the economic burden of rotavirus-associated and all-cause diarrhoea in Vellore, India.

Authors:  Andrea S Mendelsohn; Jaya Ruth Asirvatham; D Mkaya Mwamburi; T V Sowmynarayanan; Vandana Malik; Jayaprakash Muliyil; Gagandeep Kang
Journal:  Trop Med Int Health       Date:  2008-05-06       Impact factor: 2.622

5.  Disease burden and related medical costs of rotavirus infections in Taiwan.

Authors:  Chun-Yi Lu; Tsai-Ling Lauderdale; Yin-Hua Fang; Chung-Yi Wang; Yu-Huai Ho; Che-Lun Hung; Luan-Yin Chang; Chin-Yun Lee; Li-Min Huang
Journal:  BMC Infect Dis       Date:  2006-12-15       Impact factor: 3.090

6.  Anticipating rotavirus vaccines--a pre-vaccine assessment of incidence and economic burden of rotavirus hospitalizations among children < 5 year of age in Libya, 2012-13.

Authors:  Salem Alkoshi; Eyal Leshem; Umesh D Parashar; Maznah Dahlui
Journal:  BMC Public Health       Date:  2015-01-24       Impact factor: 3.295

7.  Rotavirus incidence in hospitalised Hong Kong children: 1 July 1997 to 31 March 2011.

Authors:  Grace P K Chiang; E Anthony S Nelson; Timothy J H S Pang; Shu Kei Law; W Goggins; Johnny Y C Chan; Margaret Ip; Paul K S Chan
Journal:  Vaccine       Date:  2014-02-11       Impact factor: 3.641

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.